R1 RCM (NASDAQ:RCM) Issues Earnings Results, Misses Expectations By $0.04 EPS

R1 RCM (NASDAQ:RCM) released its quarterly earnings results on Tuesday. The healthcare provider reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04), Briefing.com reports. R1 RCM had a negative net margin of 1.68% and a negative return on equity of 1.44%. The firm had revenue of $656.80 million for the quarter, compared to analyst estimates of $640.93 million. The business’s revenue was up 14.7% compared to the same quarter last year.

R1 RCM Price Performance

RCM stock traded up $0.02 during mid-day trading on Thursday, reaching $14.29. The company’s stock had a trading volume of 180,833 shares, compared to its average volume of 3,466,794. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.77. The company’s 50 day moving average is $14.18 and its two-hundred day moving average is $13.29. R1 RCM has a fifty-two week low of $8.87 and a fifty-two week high of $15.12. The stock has a market cap of $6.03 billion, a PE ratio of -95.13 and a beta of 0.84.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Stephens lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. Jefferies Financial Group downgraded R1 RCM from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. TD Cowen restated a “hold” rating and issued a $14.30 price objective (down from $20.00) on shares of R1 RCM in a research report on Monday, August 5th. Truist Financial reduced their target price on R1 RCM from $16.00 to $14.30 and set a “hold” rating for the company in a research note on Thursday, August 8th. Finally, Morgan Stanley cut shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 8th. Thirteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, R1 RCM presently has an average rating of “Hold” and a consensus target price of $15.41.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.